Switching to Gilenya® (fingolimod) from a standard interferon offers sustained freedom from disease activity for people with relapsing remitting multiple sclerosis
Pharmiweb, 10 Jun 2013
Accessed on 20 Jun 2013 from http://www.pharmiweb.com/pressreleases/pressrel.asp?ROW_ID=75633#.UcNxHo6-K4k.